13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Obesity Cell culture, mouse and non-human primate (NHP) studies suggest inhibiting the GIP receptor alone or in combination with GLP-1R agonists could help treat obesity. In a mouse model of diet-induced obesity, a mouse...
01:21 , Dec 8, 2018 |  BioCentury  |  Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
19:12 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Lilly debuts data for new Type II diabetes candidate

Eli Lilly and Co. (NYSE:LLY) reported data from a Phase IIb trial in Type II diabetics showing that high-dose LY3298176 led to improvements in HbA1c and weight loss that were better than those seen to...
20:24 , Oct 4, 2018 |  BC Extra  |  Clinical News

Novo takes hit as Lilly debuts data for new diabetes candidate

Eli Lilly and Co. (NYSE:LLY) reported data from a Phase IIb trial in Type II diabetics Thursday showing that high-dose LY3298176 led to improvements in HbA1c and weight loss that were better than those seen...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
22:04 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting GIP receptor could help treat MI. In a mouse model of MI, cardiomyocyte-specific knockout of GIP receptor increased survival and decreased left ventricular remodeling and scar formation...
22:58 , Oct 6, 2017 |  BioCentury  |  Emerging Company Profile

Metabolic contrarian

Antag Therapeutics ApS is going against the grain, blocking rather than boosting the effects of glucose-dependent insulinotropic polypeptide to treat obesity and diabetes. While several other companies are developing agonists to enhance the peptide’s glucose-regulating...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
20:42 , Jun 28, 2017 |  BC Extra  |  Financial News

Novo Seeds invests €2.7M in Antag

Metabolic start-up Antag Therapeutics ApS (Copenhagen, Denmark) said it has received a €2.7 million ($3 million) investment from Novo Seeds, the early stage investment arm of Novo Holdings A/S (Hellerup, Denmark). Antag is developing peptide...